As with all products, we will keep its safety under close review. The Medicines and Healthcare products Regulatory Agency ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood ...

Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) had 1-year ...

Lexeo Therapeutics’ gene therapy provides a healthy version of the frataxin gene, which is critical for energy production in ...

“We are incredibly proud to introduce the only Health Canada-approved treatment for FA ... Canada approves Biogen’s Skyclarys ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

Lexeo Therapeutics announces positive interim phase 1/2 data for LX2006 in Friedreich ataxia cardiomyopathy: New York Wednesday, April 9, 2025, 12:00 Hrs [IST] Lexeo Therapeutics, ...

The firm plans to use improvement in left ventricular mass index and increased frataxin protein expression after LX2006 treatment as co-primary endpoints.

Lexeo Therapeutics, Inc.’s LXEO share price has surged by 9.50%, which has investors questioning if this is right time to ...

Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 9.71%, which has investors questioning if this is right time to buy ...